SynthesisPloS one2020
The female side of pharmacotherapy for ADHD-A systematic literature review.
Synthesis in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 83 citations in OpenAlex.
- Secondary analyses of sex differences in attention improvements across three clinical trials of a digital therapeutic in children, adolescents, and adults with ADHD.BMC public health · 2024Trial
- Review
- Dynamic relationship and pleiotropic loci of attention deficit hyperactivity disorder with sleep traits.Translational psychiatry · 2026Article
- Article
- The impact of social determinants of health and trajectories of medication use on functional outcomes in children with ADHD: study protocol.BJPsych open · 2026Article
- Methylphenidate reduces rats' temporal discounting of aversive outcomes.Psychopharmacology · 2026Article
- Repeated Oral Methylphenidate Administration Evokes Changes in Brain Plasticity Proteins in Juvenile Wistar Kyoto Rats: Evidence for Sex-Related Differences.Neurochemical research · 2026Article
- Comorbidities and comedication among individuals in treatment for ADHD: a Danish nationwide study.BMC psychiatry · 2026Article
- Sex differences in the response to treatment of attention deficit hyperactivity disorder.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Dosing and Discontinuation of Methylphenidate Medication in Relation to Weight Status in Children and Adolescents.Paediatric drugs · 2026Article
- Disproportionality analysis of methylphenidate-associated adverse events in pediatric patients using the FDA Adverse Event Reporting System: overall signals and stratification by gender and dosage form.Frontiers in psychiatry · 2026Article
- Observational
- Menstrual Cycle-Related Hormonal Fluctuations in ADHD: Effect on Cognitive Functioning-A Narrative Review.Journal of clinical medicine · 2025Review
- Children and Young Adults Who Used Medication for Attention Deficit Hyperactivity Disorder Faced Increased Cardiac Risks.Acta paediatrica (Oslo, Norway : 1992) · 2025Article
- Review of Autism Spectrum Disorder (ASD): Epidemiology, Aetiology, Pathology, and Pharmacological Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Practical tools for female-specific ADHD: The impact of hormonal fluctuations in clinical practice and from the literature.European psychiatry : the journal of the Association of European Psychiatrists · 2025Review
- Clinical response to a single-dose methylphenidate challenge is indicative of treatment response at two months in adults with ADHD.Translational psychiatry · 2025Article
- Attention-deficit/hyperactivity disorder (ADHD) in adults: evidence base, uncertainties and controversies.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2025Article
- Duration of ADHD medication treatment among Finnish children and adolescents ‒ a nationwide register study.European child & adolescent psychiatry · 2025Article
- Can response to ADHD medication be predicted?European child & adolescent psychiatry · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis comprehensive review examined sex differences in prescription rates and efficacy or effectiveness of pharmacotherapy treatment in girls and women with attention deficit hyperactivity disorder (ADHD), while identifying gaps in the scientific knowledge on this topic.
methodA rigorous electronic database search was carried out in order to identify all published studies on female-specific effects of stimulants and non-stimulants in the treatment of ADHD. In total, 2672 studies were screened of which 21 studies (seven on prescription rates, 14 on effects of pharmacotherapy) met the inclusion criteria and were included for analysis.
resultsIn all seven studies on ADHD prescription rates, girls received significantly less prescriptions than boys, a difference however no longer seen in adults with the exception of one study. Each of the 14 studies on effectiveness / efficacy found at least one sex-difference in the effects of ADHD pharmacotherapy.
conclusionSeveral sex-differences are demonstrated in the prescription, usage and efficacy /effectiveness of both stimulant and non-stimulant ADHD pharmacotherapy. A single daily use of MPH may possibly not be optimal for girls with ADHD and ATX may be a promising medication for girls and women with ADHD. The robustness of this result requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.